Company Analysis
Sign in

Akanda Corp. (AKAN)

Nasdaq: AKAN · Medicinal Chemicals & Botanical Products · New Romney, GB · filing with the SEC since 2021
Full chart Alerts Compare
Grade3.8
◀ Past 4.1● Present 2.9▶ Future 4.7
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2024, as filed
Revenue$836,664+97.5%
Net income-$4.1M+87.3%
Earnings per share$-3.93+99.3%
Operating cash flow-$4.0M-165.3%
Cash$3.8M+3992.5%
Debtn/a
Shareholders’ equity$4.3M+211.7%
Shares, diluted1,042,014+1750.3%
Return on equity-95.8%
The recordfrom its filings
Filings in 202634
Newest filingNov 6 · F-1/A
Annual reportJun 9, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer category<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
192021222324
As filed, in USD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton AKAN · research, not advice